Catharina Johansson appointed new CFO, effective 1 December

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, has appointed Catharina Johansson as the company’s new CFO. She will take up her position on 1 December. This appointment concludes the recruitment process initiated earlier this year when the company’s previous CFO, Christian Svensson, announced his decision to step down, to focus on his own consulting practice.

Catharina Johansson was formerly Interim CFO of medical technology company Cellavision, listed on NASDAQ OMX Stockholm, as well as Head of Accounting at Bong and Alfa Laval Europe. She holds an M.Sc. in Business and Economics and is based in Lund, Sweden where NeuroVive’s headquarters are located.

Mikael Brönnegård, CEO of NeuroVive Pharmaceutical AB, said: “Catharina Johansson’s experience from a listed medical technology growth company with international operations means she’s well prepared for the role as CFO of NeuroVive. I’m certain that her experience and drive will be a great asset to NeuroVive when we develop our position as a leader with many international collaborations and revenue sources.”

Catharina Johansson, the new CFO of NeuroVive Pharmaceutical AB, said: “NeuroVive is right in a really interesting development phase, and I look forward to using my experience of similar positions to help move the company forward. I prefer dynamic companies that present constant challenges, so I expect to fit well into NeuroVive’s development-driven business operations.”

NeuroVive’s former CFO Christian Svensson will continue to serve the company on a consultancy basis until Catharina takes up her new position, and during a transitional phase. Accordingly, the transition is expected to be smooth, with no effect on day-to-day business.
About NeuroVive
NeuroVive Pharmaceutical AB, a leading mitochondrial medicine company, is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. These medical conditions are characterized by a pressing medicinal need and have no approved pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion® (heart attack) and NeuroSTAT® (traumatic brain injury) are currently being evaluated in phase III and phase II studies, respectively. NeuroVive’s research programs also include products for the treatment of anti-viral indications (Hepatitis B/C), brain cell injury in stroke patients, and drug candidates for cellular protection and treating mitochondria-related energy regulation diseases. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden.

Media and investor relations contact:
Ingmar Rentzhog, Laika Consulting, tel: +46 (0)46 275 6221, email:

Please also use the above contact if you wish to arrange an interview with NeuroVive’s CEO, Mikael Brönnegård.

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden, tel: +46 (0)46 275 6220 (switchboard), Fax: +46 (0)46 888 8348,,

NeuroVive Pharmaceutical AB (publ) is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication at 08:00 a.m. CEST on October 9, 2013.